study to demonstrate clinical benefit of lenalidomide and dexamethasone

Conditions: Multiple Myeloma

Summary: recent prospective multicenter phase ii study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory mm. the overall response rate was 71% including complete remission of 15%. median progression free survival and overall survival were 8.9 and 30.5 months. in addition, grade 3-4 toxicities such as neutropenia, and infections were reduced. this study supported that lower dose lenalidomide may be optimal stating dose for elderly patients with frailty.

multiple myeloma (mm) is a malignant plasma cell disorder that occurs mainly in older adults. the median age at diagnosis is approximately 70 years, and two-thirds of patients with newly diagnosed mm are older than 65years. as life expectancy increases, the population of older individuals grows. consequently, the number of patients with mm, especially elderly patients, is expected to increase considerably in the next two decades. elderly patients may have a variety of comorbidities and reduced physical function at diagnosis, and may be intolerable to standard chemotherapy. recent prospective multicenter phase ii study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory mm\[8\]. the overall response rate was 71% including complete remission of 15%. median progression free survival and overall survival were 8.9 and 30.5 months. in addition, grade 3-4 toxicities such as neutropenia, and infections were reduced. this study supported that lower dose lenalidomide may be optimal stating dose for elderly patients with frailty. therefore, investigators thought that the use of lower dose of lenalidomide in the frail group is expected to increase the effectiveness as it is used for a long time while reducing toxicity.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 70 years unfit and ineligible transplantation in patients with newly diagnosed mm. 2. patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements. 3. patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. 4. symptomatic mm based on standard crab criteria. 5. patient has measurable disease, defined as follows: * any quantifiable serum monoclonal protein value (generally, but not necessarily, ≥ 0.5 g/dl of m-protein) and, where applicable, * urine light-chain excretion of \>200 mg/24 hours. for patients with oligo or non-secretory mm, it is required that they have * measurable plasmacytoma \> 2 cm as determined by clinical examination or applicable radiographs (i.e. mri, ct-scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). we anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory mm with free light chains only in order to maximize interpretation of benefit results. 6. the frailty of the patient will be calculated by r-mci and scoring according to renal function, pulmonary function, activity, frailty, age, and cytogenetics, 0-3 points are low risk (fit) risk (inadequate) and 7 or higher will be classified as high risk (frail). only inadequate and frail can be included. 7. patients must meet the following clinical laboratory criteria with 21 days of starting treatment: * absolute neutrophil count (anc) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥ 30,000/mm3 if myeloma involvement in the bone marrow is \>50%) * total bilirubin ≤ 1.5 x the upper limit of the normal range (uln). alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 5 x uln. * calculated creatinine clearance ≥ 30ml/min or creatinine \< 3mg/dl. 8. patients who are planned to receive lenalidomide according to license of lenalidomide and must be registered the risk management program(pregnancy prevention program) of each company. exclusion criteria: 1. pregnant or lactating females. 2. male patients not agreeing to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study. 3. females of childbearing potential not agreeing to use two acceptable methods for contraception (e.g. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. 4. previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid \< to the equivalent of dexamethasone 40 mg/day for 4 days). 5. any significant medical disease or conditions that, in the investigator's opinion, may interfere with protocol adherence or subject's ability to give informed consent or could place the subject at unacceptable risk. 6. presence of clinical active infectious hepatitis type b or c, classified into child-pugh class c (see appendix v) and hiv. 7. presence of acute active infection requiring antibiotics or infiltrative pulmonary disease. 8. contraindication to any of the required drugs or supportive treatments. 9. prior history of malignancies, other than mm, unless the subject had been free of disease for \>= 3 years with the following exceptions: basal cell ca of skin, squamous cell ca of skin, ca in situ of cervix and breast, incidental histologic finding of prostate cancer (tnm stage of t1a or t1b) 10. known allergy to any of the study medications, their analogues, or excipients in the various formulations. 11. subjects with unstable cardiac disease: mi within 6 months before study participation, nyha heart failure class iii-iv, uncontrolled hypertension/atrial fibrillation, 12. conditions requiring chronic steroid/immunosuppressive therapy such as ra, ms, lupus, that likely need additional steroid/is treatment in addition to study treatment 13. grade \>=2 peripheral neuropathy 14. subjects who are unwilling or unable to undergo antithrombotic therapy